Please ensure Javascript is enabled for purposes of website accessibility

Oxford Researchers Say Their COVID-19 Vaccine Could Be Available in September

By Cory Renauer - Apr 28, 2020 at 11:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The optimistic scientists at Oxford University's Jenner Institute are speeding ahead on their SARS-CoV 2 vaccine candidate, but there are some important caveats.

Scientists at Oxford University think they have a SARS-CoV-2 vaccine candidate that can jump ahead of those under development at Johnson & Johnson, Moderna, and dozens of smaller biopharmaceutical companies. The current vaccine development record is four years from discovery to approval, but the Jenner Institute team thinks the candidate it has in clinical trials for the could be ready for the public this fall.

The Oxford team's vaccine, which it has dubbed ChAdOx1 nCoV-19, uses an increasingly popular method to deliver therapeutic DNA sequences: a non-replicating adenovirus. ChAdOx1 nCoV-19 and its predecessor, ChAdOx1 MERS, use the same adenovirus to inject genetic blueprints for the spike proteins that give coronaviruses their characteristic shape.

Microscope up close

Image source: Getty Images.

Earlier this year, a clinical trial with ChAdOx1 MERS provided some evidence the Oxford team's adenovirus vector was safe and the vaccine appeared arguably effective at preventing transmission of MERS. This allowed the recruitment of 510 volunteers for a clinical trial to begin in March; if initial results are encouraging, that study could grow to more than 6,000 participants by the end of May.

No sick monkeys

A preclinical study with non-human primates recently showed encouraging results. Researchers from the National Institutes of Health inoculated six rhesus macaque monkeys with ChAdOx1 nCoV-19, then exposed them to SARS-CoV-2, the coronavirus that causes COVID-19. After 28 days, all six monkeys were still healthy.

Sadly, the vast majority of new vaccine candidates that look promising during pre-clinical development fizzle out once their efficacy is rigorously tested in humans. While macaques are relatively close genetic relatives to humans, which makes them useful early test subjects for medicines, this sign of efficacy should be viewed as a prerequisite for investing in human clinical trials, and nothing more.

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$167.57 (0.89%) $1.48
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$167.96 (-4.99%) $-8.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.